P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001). (23rd June 2022) - Stein, E. M.; Patel, A.; Michaelis, L. C.; Schiller, G.; Swords, R.; Carvajal, L. A.; Bray, G.; DiMartino, J.; Levy, M. Y.